StockData
Puma Biotechnology, Inc. logo

Puma Biotechnology, Inc. (PBYI) stock analysis

PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3011% below fair value
$7.77−0.31 (-3.84%)

Close on Nov 13, 2026Market cap $401.09MP/E 16.9Yield –

StockData Score

Prices as of Nov 13, 2026How the score works

Value2Growth2Performance5Health5Dividend0

Mixed14 of 30 checks passed

Puma Biotechnology passes 14 of the 30 checks behind our score; 8 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
2/6
Growth
2/6
Past performance
5/6
Financial health
5/6
Dividend
0/6

What stands out

  • Trading below fair value

    The share price of $7.77 is below our fair value estimate of $8.76.

  • Return on equity over 15%

    Return on equity was 18.2% over the last twelve months and averaged 31.8% over five years.

  • Return on capital over 10%

    Return on invested capital was 38.7%, above the 10% that usually covers the cost of capital.

  • No debt

    Puma Biotechnology has no borrowings on its latest balance sheet.

What to watch

  • Margin of safety under 20%

    The price is 11.3% below fair value, less than the 20% cushion we look for.

  • Revenue growing under 10% a year

    Revenue grew 0.0% a year over the last three fiscal years, short of the 10% we look for.

  • Elevated bankruptcy risk

    The Altman Z-score is -2.31; above 3 is the safe zone and below 1.8 the distress zone.

  • P/E above its 5-year median

    Puma Biotechnology's P/E of 16.9 is above its own 5-year median of 11.8.

Valuation2/6
  • P/E above its 5-year median

    Puma Biotechnology's P/E of 16.9 is above its own 5-year median of 11.8.

  • P/E below the industry

    Puma Biotechnology's P/E of 16.9 is below the Drugs median of 25.0.

  • EV/EBITDA above its 5-year median

    Puma Biotechnology's EV/EBITDA of 8.3 is above its 5-year median of 5.8.

  • P/B above the industry

    Puma Biotechnology's price-to-book of 2.74 is above the Drugs median of 2.09.

  • Trading below fair value

    The share price of $7.77 is below our fair value estimate of $8.76.

  • Margin of safety under 20%

    The price is 11.3% below fair value, less than the 20% cushion we look for.

Growth2/6
  • Revenue growing under 10% a year

    Revenue grew 0.0% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing faster than the industry

    Revenue grew 9.4% over the last twelve months; the Drugs median is 7.7%.

  • Guidance raised

    Puma Biotechnology raised its New Full Year 2026 Total Revenue outlook on Nov 5, 2026.

  • Gross margin slipping

    Gross margin was 73.6% over the last twelve months, against 76.9% a year earlier.

Past performance5/6
  • Return on equity over 15%

    Return on equity was 18.2% over the last twelve months and averaged 31.8% over five years.

  • Return on capital over 10%

    Return on invested capital was 38.7%, above the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    Puma Biotechnology's return on equity of 18.2% is above the Drugs median of -57.0%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was 10.3% over the last twelve months, against a 5-year average of 4.9%.

  • Net margin above the industry

    Puma Biotechnology's net margin of 10.3% is above the Drugs median of -53.5%.

Financial health5/6
  • No debt

    Puma Biotechnology has no borrowings on its latest balance sheet.

  • Debt not rising

    With no debt today, leverage cannot have risen.

  • Debt covered by cash flow

    There is no debt to cover.

  • Interest well covered

    Operating income covers interest expense 12.9 times.

  • Short-term assets cover short-term debts

    Current assets are 3.03 times current liabilities.

  • Elevated bankruptcy risk

    The Altman Z-score is -2.31; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6
  • No dividend

    Puma Biotechnology has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Our estimate per share

$8.76

The share price is 11% below this estimate.

20%+ below
Near fair value
20%+ above
$7.77Price
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/E18.4×11.8×25.0×$8.4540%
EV/EBITDA11.6×5.8×17.4×$10.1035%
P/B2.8×3.5×2.1×$7.9710%
Earnings power10.0% cost of equity––$6.9615%
Fair value$8.76100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Own 5-year median 11.8
  • Drugs median 25.0

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Medium risk

Average value traded per day
$4.12M
Value traded per 1% price move
$1.63M

Downside

Medium risk

Typical loss in a bad month
18.2%
Volatility (annualized)
52%
Sharpe ratio, 1 year
0.97
Beta to the S&P 500 (5Y)
0.97

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2011 to 2025

Gross margin

74.5%−8.0 pts over 5 years

Operating margin

16.3%+29.8 pts over 5 years

Net margin

13.6%+40.3 pts over 5 years

See a number that looks wrong?